NCT07553390
Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Eligibility criteria expanded, about 49 words
- Start date changed from estimate of Oct 1, 2026 to Nov 5, 2026
- Interventions: Rimiducid (Drug), TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (Drug), Trastuzumab deruxtecan (T-DXd) (Drug) to Rimiducid (Drug), TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (Drug), Trastuzumab deruxtecan (T-DXd) (Drug)
- Study description revised
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
This phase will be conducted with a maximum of 21 participants to examine three escalating cell dose levels and one de-escalating cell dose level (level -1) with T-Dxd (21 days +/-3 days interval between cell infusion and each dose of T-Dxd treatment), to determine the safety and select the RP2D.
Investigators will enroll two cohorts of participants with up to 15 participants within each cohort to the RP2D to further evaluate the safety and preliminary efficacy.
Drugs: TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid
Sites
1 site in 1 country
- UT MD AndersonHouston, Texas, United States